Illumina, Inc. (NASDAQ:ILMN) Receives $123.17 Consensus Target Price from Brokerages

Key Points

• Illumina, Inc. has received an average recommendation of "Hold" from 19 brokerage firms, with two sell ratings, eleven holds, and six buy recommendations.
• The average 12-month target price for Illumina's stock is $123.17, with recent ratings adjusting targets to between $105.00 and $125.00.
• Illumina reported $1.19 EPS for the last quarter, surpassing consensus estimates of $1.02, despite a 4.8% year-over-year revenue decline.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has received an average recommendation of "Hold" from the nineteen analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $123.0556.

A number of brokerages recently weighed in on ILMN. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target for the company. in a research report on Tuesday, August 12th. Guggenheim dropped their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a research report on Tuesday. Finally, Stephens set a $110.00 target price on shares of Illumina and gave the company an "overweight" rating in a research note on Monday, August 4th.

Illumina Trading Down 1.8%

Shares of Illumina stock traded down $1.75 on Tuesday, hitting $96.07. 1,163,473 shares of the company traded hands, compared to its average volume of 1,426,234. The company has a market cap of $14.77 billion, a PE ratio of 12.16, a PEG ratio of 2.25 and a beta of 1.43. Illumina has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock's 50 day moving average price is $99.42 and its 200-day moving average price is $88.53.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts predict that Illumina will post 4.51 EPS for the current year.

Hedge Funds Weigh In On Illumina

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rise Advisors LLC increased its position in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 115 shares during the last quarter. Rakuten Securities Inc. increased its holdings in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares during the last quarter. Center for Financial Planning Inc. bought a new position in Illumina during the first quarter worth $33,000. Finally, Fourth Dimension Wealth LLC acquired a new stake in Illumina during the fourth quarter worth about $40,000. Institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.